I.E. Chazova, MD., PhD., Prof; V.V. Fomin, MD., PhD.; E.M. Paltseva MD., PhD.
Russian Cardiological Scientific Industrial Complex, I.M. Sechenov Moscow Medical Academy
The interest to direct pharmacological active renin blockade is explained by the need of its homodynamic and tissue effects removing, that are realized mostly through interaction with pro-renin receptors. Renin activity control provides the effective control of the activity of the most RAAS components. Direct renin inhibitor aliskiren with proven in large clinical trials efficacy can be especially effective at hypertensive patients for kidney injury prevention.